Alnylam Pharmaceuticals Inc (ALNY)
244.89
-1.91
(-0.77%)
USD |
NASDAQ |
Nov 22, 16:00
246.38
+1.49
(+0.61%)
After-Hours: 20:00
Alnylam Pharmaceuticals Revenue (TTM): 2.095B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.095B |
| June 30, 2024 | 2.344B |
| March 31, 2024 | 2.003B |
| December 31, 2023 | 1.828B |
| September 30, 2023 | 1.724B |
| June 30, 2023 | 1.237B |
| March 31, 2023 | 1.143B |
| December 31, 2022 | 1.037B |
| September 30, 2022 | 960.92M |
| June 30, 2022 | 884.24M |
| March 31, 2022 | 879.98M |
| December 31, 2021 | 844.29M |
| September 30, 2021 | 749.31M |
| June 30, 2021 | 687.53M |
| March 31, 2021 | 570.94M |
| December 31, 2020 | 492.85M |
| September 30, 2020 | 400.97M |
| June 30, 2020 | 345.18M |
| March 31, 2020 | 285.93M |
| December 31, 2019 | 219.75M |
| September 30, 2019 | 169.10M |
| June 30, 2019 | 101.11M |
| March 31, 2019 | 86.30M |
| December 31, 2018 | 74.91M |
| September 30, 2018 | 91.80M |
| Date | Value |
|---|---|
| June 30, 2018 | 106.83M |
| March 31, 2018 | 92.85M |
| December 31, 2017 | 89.91M |
| September 30, 2017 | 69.44M |
| June 30, 2017 | 66.00M |
| March 31, 2017 | 58.77M |
| December 31, 2016 | 47.16M |
| September 30, 2016 | 37.26M |
| June 30, 2016 | 29.93M |
| March 31, 2016 | 29.90M |
| December 31, 2015 | 41.10M |
| September 30, 2015 | 57.56M |
| June 30, 2015 | 62.21M |
| March 31, 2015 | 60.82M |
| December 31, 2014 | 50.56M |
| September 30, 2014 | 37.39M |
| June 30, 2014 | 35.41M |
| March 31, 2014 | 36.80M |
| December 31, 2013 | 47.17M |
| September 30, 2013 | 44.82M |
| June 30, 2013 | 52.58M |
| March 31, 2013 | 64.78M |
| December 31, 2012 | 66.72M |
| September 30, 2012 | 78.68M |
| June 30, 2012 | 82.72M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
219.75M
Minimum
Dec 2019
2.344B
Maximum
Jun 2024
1.037B
Average
882.11M
Median
Revenue (TTM) Benchmarks
| Pfizer Inc | 59.37B |
| BridgeBio Pharma Inc | 217.76M |
| Gilead Sciences Inc | 28.30B |
| Johnson & Johnson | 87.70B |
| Biomarin Pharmaceutical Inc | 2.753B |